2025
Scribe Therapeutics Prepares for Clinical Trials by Streamlining Workforce Amid Advances in Cardiometabolic Genetic Medicines
Scribe Therapeutics, cardiometabolic disease, CRISPR, gene editing, epigenetic modification, clinical trials, workforce reduction
Velia Therapeutics Closes Operations, Remains Committed to Microprotein Therapeutic Potential
Velia Therapeutics, microproteins, biotechnology, therapeutic potential, company closure
Novo Nordisk and Lilly Lead Clarivate’s 2025 ‘Drugs to Watch’ List with Breakthrough Therapies
Clarivate, Drugs to Watch 2025, Novo Nordisk, Eli Lilly, Obesity treatments, Gene therapy, Oncology, Blockbuster drugs, Pharmaceutical industry
LB Pharma’s Novel Antipsychotic LB-102 Shows Promising Phase II Results for Schizophrenia
Schizophrenia treatment, Antipsychotic drugs, Clinical trial results, Benzamide class, LB-102
LB Pharma’s Phase II Success Revitalizes Benzamide Antipsychotics for US Schizophrenia Treatment
LB-102, schizophrenia, benzamide antipsychotics, Phase II trial, efficacy, safety
LB Pharma’s Novel Antipsychotic LB-102 Shows Promising Phase II Results for Schizophrenia
LB-102, schizophrenia, antipsychotic, Phase II trial, benzamide class
LB-102 Shows Promise as Potential First-in-Class Benzamide Antipsychotic for Schizophrenia
LB-102, schizophrenia, Phase 2 trial, benzamide antipsychotic, efficacy, safety
LB Pharma’s Phase II Success Revives Promising Antipsychotic Class for US Patients with Schizophrenia
LB-102, schizophrenia, Phase II trial, antipsychotic, benzamide class
LB-102 Shows Promise as Potential First-in-Class Benzamide Antipsychotic for Schizophrenia in US
LB-102, schizophrenia, Phase 2 trial, benzamide antipsychotic, efficacy, safety
LB Pharma’s Novel Antipsychotic LB-102 Shows Promise in Phase II Schizophrenia Trial
LB-102, Benzamide antipsychotic, Schizophrenia treatment, Phase II clinical trial, PANSS score reduction, First-in-class potential